CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • MDWD Dashboard
  • Financials
  • Filings
  • Transcripts
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 6-K Filing

MediWound (MDWD) 6-KMediWound Announces Positive Topline Results from Phase 3 Pediatric

Filed: 20 Jul 21, 7:05am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 MediWound Announces Positive Topline Results from Phase 3 Pediatric
    MDWD similar filings
    • 10 Aug 21 MediWound Reports Second Quarter Financial Results
    • 28 Jul 21 MediWound Announces Positive Outcome of Interim Assessment for its
    • 26 Jul 21 MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
    • 20 Jul 21 MediWound Announces Positive Topline Results from Phase 3 Pediatric
    • 29 Jun 21 MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid
    • 15 Jun 21 Current report (foreign)
    • 5 May 21 Current report (foreign)
    Filing view
    Share this filing

     
    SECURITIES AND EXCHANGE COMMISSION
     
    Washington, D.C.  20549
    ______________________
     
    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER
     
    Pursuant to Rule 13a-16 or 15d-16 of the
    Securities Exchange Act of 1934
     
    For the month of July 2021
     
    Commission File Number: 001-36349
     
                      MediWound Ltd.                   
    (Translation of registrant's name into English)
     
    42 Hayarkon Street
    Yavne, 8122745 Israel
     (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
     
    Form 20-F ☒            Form 40-F ☐  

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐  
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ 
     

     
    EXPLANATORY NOTE
     
    On July 20, 2021, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns". A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

    The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company) is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020 and May 15, 2021 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-195517, 333-210375, 333-230487, 333-236635 and 333-255784, respectively) and on Form F-3 filed with the SEC on March 25, 2019 (Registration No. 333-230490).


    2

     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    Date: July 20, 2021     
    MEDIWOUND LTD.

    By:  /s/ Boaz Gur-Lavie
    Name:  Boaz Gur-Lavie
    Title:    Chief Financial Officer


    3


    EXHIBIT INDEX

    The following exhibit is filed as part of this Form 6-K:

    Exhibit

    99.1
    Description

    Press release dated July 20, 2021 titled "MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns".


    4

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn